The problem of cancer care in the context of a coronavirus pandemic

May 12, 2020

Today, much attention is paid to the category of people who are at risk of COVID-19 infection. The greatest risk of getting infection is observed in people of old age, with increasing mortality exponentially from about 65. Many articles have been published that oncological patients are mostly susceptible to coronavirus infection. The treatment of malignant pathology should be guided by two basic principles in the pandemia of COVID-19: the patient’s desire to receive treatment and the risk/bene­fit ratio. An oncological patient has limited time to decide whether or not to be treated. If we talk about the benefits of anti-tumor treatment, it should be remembered that correctly diagnosed cancer and its treatment in the early stages makes it possible to completely remove the tumor, which, in turn, significantly increases the chances of recovery. Timely treatment started in the advanced stages can significantly improve the quality of life of patients and achieve long-term remission of the disease. The decision to start antitumor treatment or to temporarily delay it, when it has already been initiated, is made individually in each case. In summary, the risk/benefit ratio is a kind of balance between what needs to be treated first and what «can wait» under general quarantine measures due to COVID-19.


  • 24 Zdorovia (2020) Skilky ukraintsiv pomyraiut vid raku: strashna statystyka ( statistika_n1133336).
  • MOZ ukrainy (2020) Operatyvna informatsiia pro poshyrennia koronavirusnoi infektsii COVID-19 (
  • Fisher D. (2020) bez suvoroho karantynu. yak Sinhapur spravliaietsia z koronavirusom (
  • (2020) Za dva misiatsi v Ukraini pomerly 100,7 tys. osib, z nykh 68,5 tys. vid khvorob systemy krovoobihu, — Derzhstat (
  • ASCO (2020) COVID-19 Patient Care Information (
  • Desai A., Sachdeva S., Parekh T., Desai R. (2020) COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis. JCO Global Oncol., 6: 557–559. DOI: 10.1200/GO.20.00097.
  • Liang W., Guan W., Chen R. at al. (2020) Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol., 21(3): 335–337. DOI:
  • Ma J., Yin J., Qian Y., Wu Y. (2020) Clinical characteristics and prognosis in cancer patients with COVID-19: A single center’s retrospective study. J. Infect., pii: S0163-4453(20)30214-0. doi: 10.1016/j.jinf.2020.04.006.
  • Oh W. (2020) COVID-19 infection in cancer patients: early observations and unanswered questions. Ann. Oncol., pii: S0923-7534(20)36384-5. DOI:
  • Wang H., Zhang L. (2020) Risk of COVID-19 for patients with cancer. Lancet, 21(4): E181. DOI:
  • WHO (2020) Coronavirus disease (COVID-19) Pandemic (
  • Xia Y., Jin R., Zhao J. et al. (2020) Risk of COVID-19 for patients with cancer. Lancet, 21(4): E181. DOI:
  • Yu J., Ouyang W., Chua M.L.K., Xie C. (2020) SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol., Mar. 25 [Epub ahead of print]. doi: 10.1001/jamaoncol.2020.0980.
  • Zhang H., Xie C., Huang Y. (2020) Treatment and Outcome of a Patient With Lung Cancer Infected With Severe Acute Respiratory Syndrome Coronavirus-2. J. Thor. Oncol., 15(5): e63–e64. DOI:
  • Zhang L., Zhu F., Xie L. et al. (2020) Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann. Oncol., pii: S0923-7534(20)36383-3. DOI: